Drug Trial Radar · NCT05484622
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Actual
Start
Jan 20, 2023
Primary completion
Feb 12, 2026
Study completion Aug 30, 2027
Sponsor
- Lead sponsor
- Institut de Recherches Internationales ServierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Aug 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
Conditions
- Astrocytoma
- Oligodendroglioma
Interventions
VorasidenibDrug
Administered orally as tablets.
PembrolizumabDrug
Administered as IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Lead-in Phase: Percentage of Participants With Dose-limiting Toxicities (DLTs)Time frame: First 21 days of dosing (Cycle 1) in safety lead-in phase
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: approximately up to 19 months
- Percentage of Tumor-infiltrating Lymphocyte (TIL) Cells in Surgically Resected Tumors Following Treatment With Vorasidenib + Pembrolizumab Compared to Untreated Control TumorsTime frame: approximately 2 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California, Los Angeles (Site: 840113)
Los Angeles, California
University of California, San Francisco (Site: 840149)
San Francisco, California
University of Colorado
Aurora, Colorado
University of Miami (Site: 840129)
Miami, Florida
Northwestern University (Site: 840123)
Chicago, Illinois
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital (Site: 840104)
Boston, Massachusetts
Dana-Farber Cancer Institute (Site: 840139)
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Memorial Sloan Kettering Cancer Center (Site: 840117)
New York, New York
Duke University (Site: 840110)
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
Mayo Clinic Florida
Cleveland, Ohio
University of Pennsylvania Health System
Philadelphia, Pennsylvania
MD Anderson Cancer Center (Site: 840102)
Houston, Texas
University of Utah, Huntsman Cancer Center
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.